Journal
RADIOGRAPHICS
Volume 41, Issue 6, Pages 1802-1818Publisher
RADIOLOGICAL SOC NORTH AMERICA (RSNA)
DOI: 10.1148/rg.2021210014
Keywords
-
Ask authors/readers for more resources
Transarterial radioembolization (TARE) with yttrium 90 is increasingly being used for the treatment of hepatocellular carcinoma (HCC). Initially used as a palliative therapy for advanced HCC, recent advancements have expanded its application to different stages of treatment. Evaluating the therapeutic response to TARE is challenging and requires appropriate tools and methods to optimize treatment outcomes for patients.
Transarterial radioembolization (TARE) with yttrium 90 has increasingly been performed to treat hepatocellular carcinoma (HCC).TARE was historically used as a palliative lobar therapy for patients with advanced HCC beyond surgical options, ablation, or transarterial chemoembolization, but recent advancements have led to its application across the Barcelona Clinic Liver Cancer staging paradigm. Newer techniques, termed radiation lobectonly and radiation segmentectorny, are being performed before liver resection to facilitate hypertrophy of the future liver remnant, before liver transplant to bridge or downstage to transplant, or as a definite curative treatment. Imaging assessment of therapeutic response to TARE is challenging as the intent of TARE is to deliver local high-dose radiation to tumors through microembolic microspheres, preserving blood flow to promote radiation injury to the tumor. Because of the microembolic nature, early imaging assessment after TARE cannot rely solely on changes in size. Knowledge of the evolving methods of TARE along with the tools to assess posttreatment imaging and response is essential to optimize TARE as a therapeutic option for patients with HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available